Indorenate

Indorenate (TR-3369), is a tryptamine derivative which acts as an agonist at the 5-HT_1A, 5-HT_1B and 5-HT_2C serotonin receptors. It has anxiolytic, antihypertensive and anorectic effects, predominantly through action at 5-HT_1A, but with some contribution from the 5-HT_1B and 5-HT_2C subtypes, and possibly some other non-serotonergic targets also.[1][2][3][4][5][6][7][8][9]

Indorenate

Identifiers
IUPAC name methyl 3-amino-2-(5-methoxy-1H-indol-3-yl)propanoate
CAS Number	73758-06-2^Y
PubChem CID	71987
ChemSpider	64989^N
UNII	AV9L041QA4
CompTox Dashboard (EPA)	DTXSID2048400
Chemical and physical data
Formula	C13H16N2O3
Molar mass	248.282 g·mol^−1
3D model (JSmol)	Interactive image
SMILES COC(=O)C(CN)c1c[nH]c(ccc2OC)c1c2
InChI InChI=1S/C13H16N2O3/c1-17-8-3-4-12-9(5-8)11(7-15-12)10(6-14)13(16)18-2/h3-5,7,10,15H,6,14H2,1-2H3^N Key:YFEDJMLMWJSRJJ-UHFFFAOYSA-N^N
^NY (what is this?)  (verify)

See also

• 5-Methoxytryptamine
• Acetryptine

References

1. Antonaccio MJ, Kerwin L (1981). "On the effects and mechanism of action of the antihypertensive agent TR 3369 (5-methoxytryptamine beta-methylcarboxylate) in spontaneously hypertensive rats". Journal of Cardiovascular Pharmacology. 3 (6): 1306–11. doi:10.1097/00005344-198111000-00018. PMID 6173531.
2. Schoeffter P, Hoyer D (November 1988). "Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus". British Journal of Pharmacology. 95 (3): 975–85. doi:10.1111/j.1476-5381.1988.tb11728.x. PMC 1854240. PMID 3207999.
3. Fernández-Guasti A, Escalante A, Hong E, Agmo A (September 1990). "Behavioural actions of the serotonergic anxiolytic indorenate". Pharmacology Biochemistry and Behavior. 37 (1): 83–8. doi:10.1016/0091-3057(90)90045-J. PMID 1979877.
4. López Cabrera M, Velázquez Martínez DN, Prado R, García G, Ortiz R (1991). "Effects of the intracerebroventricular administration of indorenate and fenfluramine on spontaneous behavior and food intake in rats". Proceedings of the Western Pharmacology Society. 34: 465–8. PMID 1788330.
5. Velázquez-Martínez DN, López Cabrera M, Sánchez H, Ramírez JI, Hong E (March 1999). "Discriminative stimulus properties of indorenate, a serotonin agonist". Journal of Psychiatry & Neuroscience. 24 (2): 122–30. PMC 1188992. PMID 10212554.
6. Sánchez H, Velázquez-Martínez DN (March 2001). "Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats". Journal of Psychopharmacology (Oxford, England). 15 (1): 29–36. doi:10.1177/026988110101500106. PMID 11277605.
7. Miranda F, Orozco G, Velázquez-Martínez DN (July 2002). "Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist". Behavioural Pharmacology. 13 (4): 303–11. doi:10.1097/00008877-200207000-00007. PMID 12218511.
8. Miranda F, Hong E, Sánchez H, Velázquez-Martínez DN (January 2003). "Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT 1A/1B/2C receptors". Pharmacology Biochemistry and Behavior. 74 (2): 371–80. doi:10.1016/S0091-3057(02)01010-9. PMID 12479957.
9. López-Meraz ML, Neri-Bazán L, Rocha L (September 2006). "Indorenate modifies a1-adrenergic and benzodiazepine receptor binding in the rat brain: an autoradiography study". The Journal of Pharmacy and Pharmacology. 58 (9): 1243–8. doi:10.1211/jpp.58.9.0011. PMID 16945183.